RPG Life Sciences completes acquisition of Actis Generics Private Limited
RPG LifeScience. · Pharmaceuticals & Biotechnology
What the filing says
- RPG Active Pharma Limited executed Share Purchase Agreement to acquire entire stake in Actis Generics Private Limited.
- Transaction completed on September 24, 2026, making Actis a subsidiary of RPG Life Sciences and wholly owned subsidiary of RPGAP.
- Intimation submitted under Regulation 30 of SEBI Listing Regulations to NSE and BSE.
Why it's rated notable: The completed acquisition of the entire stake of Actis Generics is binding, but the filing states no consideration or financial size for Actis, so the level is set at medium.
Original filing
Update On Share Purchase Agreement
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other acquisition / merger filings this fortnight
- Acquisition / mergerSwelect EnergySwelect Energy Systems to acquire 100% shares of Sushma Solar Energy Pvt Ltd
- Acquisition / mergerUgro Capital LtdUGRO Capital Ltd announces NCLT hearing date for amalgamation scheme with Profectus
- Acquisition / mergerCyient LtdCyient Limited announces Q2 and H1 FY27 financial results and corporate updates
- Acquisition / mergerSagilitySagility Limited reports Q2 FY27 financial results and declares interim dividend
- Acquisition / mergerShyam Metalics & Energy LtdShyam Sel and Power Ltd seeks NCLT approval for scheme to amalgamate Shree Venkateshwara Electrocast Pvt Ltd
- Acquisition / mergerPetronet LNG LtdPetronet LNG signs binding term sheet with Gruner Renewable for CBG JV
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.